Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cip palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cip palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cipla palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cipla palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin - cipla palbociclib is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - film coated tablet - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide crospovidone opadry green 03k110010 magnesium stearate microcrystalline cellulose succinic acid - palbociclib pfizer is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: · in combination with an aromatase inhibitor; · in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - film coated tablet - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - palbociclib pfizer is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: · in combination with an aromatase inhibitor; · in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - film coated tablet - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - palbociclib pfizer is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: · in combination with an aromatase inhibitor; · in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - breast neoplasms - antineoplastic agents - ibrance is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.in pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - palbociclib (unii: g9zf61le7g) (palbociclib - unii:g9zf61le7g) - ibrance is indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: none. risk summary based on findings from animal studies and its mechanism of action, ibrance can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of palbociclib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at maternal exposures that were ≥4 times the human clinical exposure based on auc (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, palbociclib was administered orally for 15 days before mating through to day 7 of pregnancy, which did not cause embryo toxicity at doses up to 300 mg/kg/day with maternal systemic exposures approximately 4 times the human exposure (auc) at the recommended dose. in embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of palbociclib up to 300 mg/kg/day and 20 mg/kg/day, respectively, during the period of organogenesis. the maternally toxic dose of 300 mg/kg/day was fetotoxic in rats, resulting in reduced fetal body weights. at doses ≥100 mg/kg/day in rats, there was an increased incidence of a skeletal variation (increased incidence of a rib present at the seventh cervical vertebra). at the maternally toxic dose of 20 mg/kg/day in rabbits, there was an increased incidence of skeletal variations, including small phalanges in the forelimb. at 300 mg/kg/day in rats and 20 mg/kg/day in rabbits, the maternal systemic exposures were approximately 4 and 9 times the human exposure (auc) at the recommended dose, respectively. cdk4/6 double knockout mice have been reported to die in late stages of fetal development (gestation day 14.5 until birth) due to severe anemia. however, knockout mouse data may not be predictive of effects in humans due to differences in degree of target inhibition. risk summary there is no information regarding the presence of palbociclib in human milk, its effects on milk production, or the breastfed infant. because of the potential for serious adverse reactions in breastfed infants from ibrance, advise a lactating woman not to breastfeed during treatment with ibrance and for 3 weeks after the last dose. pregnancy testing based on animal studies, ibrance can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. females of reproductive potential should have a pregnancy test prior to starting treatment with ibrance. contraception females ibrance can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with ibrance and for at least 3 weeks after the last dose. males because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with ibrance and for 3 months after the last dose [see nonclinical toxicology (13.1)] . infertility males based on animal studies, ibrance may impair fertility in males of reproductive potential [see nonclinical toxicology (13.1)] . the safety and efficacy of ibrance in pediatric patients have not been studied. altered glucose metabolism (glycosuria, hyperglycemia, decreased insulin) associated with changes in the pancreas (islet cell vacuolation), eye (cataracts, lens degeneration), kidney (tubule vacuolation, chronic progressive nephropathy) and adipose tissue (atrophy) were identified in a 27 week repeat-dose toxicology study in rats that were immature at the beginning of the studies and were most prevalent in males at oral palbociclib doses ≥30 mg/kg/day (approximately 11 times the adult human exposure [auc] at the recommended dose). some of these findings (glycosuria/hyperglycemia, pancreatic islet cell vacuolation, and kidney tubule vacuolation) were present with lower incidence and severity in a 15 week repeat-dose toxicology study in immature rats. altered glucose metabolism or associated changes in the pancreas, eye, kidney and adipose tissue were not identified in a 27-week repeat-dose toxicology study in rats that were mature at the beginning of the study and in dogs in repeat-dose toxicology studies up to 39 weeks duration. toxicities in teeth independent of altered glucose metabolism were observed in rats. administration of 100 mg/kg palbociclib for 27 weeks (approximately 15 times the adult human exposure [auc] at the recommended dose) resulted in abnormalities in growing incisor teeth (discolored, ameloblast degeneration/necrosis, mononuclear cell infiltrate). other toxicities of potential concern to pediatric patients have not been evaluated in juvenile animals. of 444 patients who received ibrance in paloma-2, 181 patients (41%) were ≥65 years of age and 48 patients (11%) were ≥75 years of age. of 347 patients who received ibrance in paloma-3, 86 patients (25%) were ≥65 years of age and 27 patients (8%) were ≥75 years of age. no overall differences in safety or effectiveness of ibrance were observed between these patients and younger patients. no dose adjustment is required in patients with mild or moderate hepatic impairment (child-pugh classes a and b). for patients with severe hepatic impairment (child-pugh class c), the recommended dose of ibrance is 75 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days [see dosage and administration (2.2)] . based on a pharmacokinetic trial in subjects with varying degrees of hepatic function, the palbociclib unbound exposure (unbound aucinf ) decreased by 17% in subjects with mild hepatic impairment (child-pugh class a), and increased by 34% and 77% in subjects with moderate (child-pugh class b) and severe (child-pugh class c) hepatic impairment, respectively, relative to subjects with normal hepatic function. peak palbociclib unbound exposure (unbound cmax ) increased by 7%, 38% and 72% for mild, moderate and severe hepatic impairment, respectively, relative to subjects with normal hepatic function [see clinical pharmacology (12.3)] . review the full prescribing information for the aromatase inhibitor or fulvestrant for dose modifications related to hepatic impairment. no dose adjustment is required in patients with mild, moderate, or severe renal impairment (crcl >15 ml/min). based on a pharmacokinetic trial in subjects with varying degrees of renal function, the total palbociclib exposure (aucinf ) increased by 39%, 42%, and 31% with mild (60 ml/min ≤ crcl <90 ml/min), moderate (30 ml/min ≤ crcl <60 ml/min), and severe (crcl <30 ml/min) renal impairment, respectively, relative to subjects with normal renal function. peak palbociclib exposure (cmax ) increased by 17%, 12%, and 15% for mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function. the pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis [see clinical pharmacology (12.3)] .